

**PRO PAIRA**  
Dermatology Inspired

# Niaben RA Cream

*For Hyper Pigmentation*



[www.propaira.com.au](http://www.propaira.com.au)

For info pack and samples contact [bh@propaira.com](mailto:bh@propaira.com)

## ORIGINAL RESEARCH

# Characteristics, treatment and outcomes of 589 melanoma patients documented by 27 general practitioners on the Skin Cancer Audit Research Database

Jeremy Hay<sup>1</sup>  | Jeff Keir<sup>2</sup>  | Clara Jimenez Balcels<sup>5</sup>  | Nikita Rosendahl<sup>4</sup>  |  
 Martelle Coetzer-Botha<sup>2</sup>  | Tobias Wilson<sup>5</sup> | Simon Clark<sup>4,6</sup>  | Astrid Baade<sup>7</sup> |  
 Cath Becker<sup>8,9</sup> | Luke Bookallil<sup>10</sup> | Chris Clifopoulos<sup>2</sup> | Tony Dicker<sup>2</sup> |  
 Martin Paul Denby<sup>11</sup> | Douglas Duthie<sup>12</sup> | Charles Elliott<sup>15</sup> | Paul Fishburn<sup>2</sup> |  
 Mark Foley<sup>14</sup> | Mark Franck<sup>15</sup>  | Irene Giam<sup>16</sup> | Patricio Gordillo<sup>17</sup> |  
 Alister Lilleyman<sup>18</sup> | Roger Macauley<sup>19</sup> | James Maher<sup>20</sup> | Ewen McPhee<sup>21</sup>  |  
 Michael Reid<sup>22</sup> | Bob Shirlaw<sup>25</sup> | Graeme Siggs<sup>24</sup>  | Robert Spark<sup>25</sup> | John Stretch<sup>26</sup> |  
 Keith van Den Heever<sup>27</sup> | Thinus van Rensburg<sup>28</sup> | Chris Watson<sup>29</sup> |  
 Harald Kittler<sup>30</sup>  | Cliff Rosendahl<sup>2,6</sup> 

<sup>1</sup>Upper Hutt Skin Clinic, Upper Hutt, Wellington, New Zealand, <sup>2</sup>General Practice Clinical Unit, Medical School, The University of Queensland, Australia, <sup>3</sup>4D Skin Cancer Clinic, Belmont North, New South Wales, Australia, <sup>4</sup>Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia, <sup>5</sup>SCARD, Brisbane, Queensland, Australia, <sup>6</sup>Tehran University of Medical Sciences, Tehran, Iran, <sup>7</sup>Gladstone GP Superclinic, Gladstone, Queensland, Australia, <sup>8</sup>Wairarapa Skin Clinic, Masterton, New Zealand, <sup>9</sup>Wairarapa Hospital, Lansdowne, Masterton, New Zealand, <sup>10</sup>The University of New England, Armidale, New South Wales, Australia, <sup>11</sup>Silverdale Medical, Silverdale, Auckland, New Zealand, <sup>12</sup>Darwin Skin Cancer Clinic, Parap, Northwest Territories, Australia, <sup>13</sup>Solarderm Skin Cancer Practice, Caboolture, Queensland, Australia, <sup>14</sup>The Skin Clinic, Marlborough – Blenheim, New Zealand, <sup>15</sup>MoleSafe Skin Cancer Clinic, Windsor, Victoria, Australia, <sup>16</sup>Skin<sup>2</sup> Clinic, Deakin, Australian Capital Territory, Australia, <sup>17</sup>Cairns Skin Cancer Clinic, Cairns, Queensland, Australia, <sup>18</sup>Newcastle Skin Check, Charlestown, New South Wales, Australia, <sup>19</sup>Bateau Bay Medical Centre, Bateau Bay, New South Wales, Australia, <sup>20</sup>Skin Cancer Ballarat, Alfredton, Victoria, Australia, <sup>21</sup>Emerald Medical Group, Emerald, Queensland, Australia, <sup>22</sup>Nelson Bay Skin Cancer Clinic, Nelson Bay, New South Wales, Australia, <sup>23</sup>Lakeside Medical, Springfield Lakes, Queensland, Australia, <sup>24</sup>Regency Medical Clinic, Sefton Park, South Australia, Australia, <sup>25</sup>Toukley Family Practice, Toukley, New South Wales, Australia, <sup>26</sup>Bond University, Robina, Queensland, Australia, <sup>27</sup>CQ Skin Cancer Clinic, Bucasia, Queensland, Australia, <sup>28</sup>Kippax Ochre Medical Centre, Holt, Australian Capital Territory, Australia, <sup>29</sup>Brisbane City Doctors, Brisbane, Queensland, Australia, and <sup>30</sup>Vienna Dermatologic Imaging Research Group, Department of Dermatology, Medical University of Vienna, Vienna, Austria

Correspondence: Prof Cliff Rosendahl, Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Australia. Address: PO Box 734, Capalaba, 4157, Australia. Email: c.rosendahl@uq.edu.au

Conflict of interest: Tobias Wilson is Managing Director and Cliff Rosendahl is the Clinical Director of SCARD Systems Pty Ltd. Cliff Rosendahl does not receive, and never has received, payment of any type from SCARD Systems Pty. Ltd.

Submitted 3 January 2022; revised 24 February 2022; accepted 26 March 2022.

## ABSTRACT

**Background and objective:** General practitioners manage more melanomas than dermatologists or surgeons in Australia. Previously undescribed, the management and outcomes of melanoma patients treated by multiple Australasian general practitioners are examined.

**Methods:** The characteristics, management and outcomes of 589 melanoma patients, managed by 27 Australasian general practitioners and documented on the Skin Cancer Audit Research Database (SCARD), were analysed.

**Results:** Most patients (58.9%) were males with mean age at diagnosis of 62.7 years (range 18–96), and most melanomas were *in situ* or thin-invasive. Patients aged under 40 years had fewer melanomas, but a higher proportion (the majority) were invasive, compared with older patients ( $P < 0.0001$ ).

Most (55.9%) melanomas were diagnosed following elliptical excision biopsy, the rate of unintended involved margins being eightfold higher for shave biopsies. Wide re-excision was performed by the treating general practitioner for most (74.9%) melanomas, with thick melanomas preferentially referred to surgeons. The average Breslow thickness of invasive melanomas re-excised by general practitioners was 0.67 mm compared with 1.99 mm for those referred to other specialists ( $P < 0.0001$ ). Of 205 patients with invasive melanoma, 14 progressed to metastatic disease, 50% of these being associated with nodular melanoma. Nine patients progressed to melanoma-specific death. The 5-year survival rate for patients with invasive melanoma was 95.2% (95% CI: 91.2–98.5%).

**Conclusions:** Diagnostic and therapeutic management of a series of melanoma patients by Australasian general practitioners were closely aligned with current guidelines and 5-year survival with respect to invasive melanoma was at least as favourable as national population-based metrics.

**Key words:** general practice, general practitioner, melanoma, melanoma 5-year survival, melanoma management, melanoma outcomes, primary care, SCARD.

## INTRODUCTION

Cutaneous melanoma is the third most common major cancer in Australia and New Zealand and the leading cause of skin cancer death in both countries.<sup>1,2</sup> General practitioners (GPs) manage more melanomas than either dermatologists or surgeons in Australia, and their proportion increased from 43% to 49% between 2003 and 2014.<sup>3</sup> This change has occurred in the context of a rise in the rate of melanoma *in situ* diagnosis relative to invasive melanoma.<sup>4</sup> The increase in management by GPs has raised questions about the quality of management in that setting, for which limited data are available.<sup>5</sup>

Relevant to management outcomes, the 5-year survival rate for primary invasive cutaneous melanoma was 92% in Australia in 2013–2017<sup>5</sup> and 90% in New Zealand in 2010–2011.<sup>6</sup>

In this retrospective, cross-sectional study of 637 melanomas managed by 27 GPs in Australia and New Zealand in 2013, we have evaluated the characteristics of the

589 patients, the diagnostic and therapeutic management, and the related outcomes. The characteristics of the 637 melanomas in this study have been previously described.<sup>7</sup>

## METHODS

This study is based on a subset of the Skin Cancer Audit Research Database (SCARD) concerning patients treated during 2013.

SCARD was established in 2007 as a free, patient safety, lesion-tracking, self-audit and research tool for professionals managing skin malignancies.<sup>7</sup> Its functions and workflow have been described.<sup>8</sup> Over one million unique lesions from over 415 000 patients have been entered on SCARD by more than 1300 practitioners, the majority being GPs working in Australasia.<sup>7</sup>

We invited GPs who guaranteed completeness of data during 2013, to participate in the study. Twenty-seven consented, 24 from Australia and 3 from New Zealand, representing 18.6% of those on SCARD in 2013, who contributed 35.6% of the melanomas diagnosed that year.<sup>7</sup>

Data drawn directly from SCARD included coded patient and lesion identifiers, patient demographics, diagnostic data, biopsy and management data and histopathological diagnosis. Further data were added during 2020 *via* a questionnaire built into the GPs' SCARD interfaces. Patients with unknown survival status were deemed lost to follow-up. Additional information was obtained by correspondence with participants when clarification was necessary.

This is a retrospective, observational study, on de-identified data, and ethics exemption #2019000909 was granted by the Ethics Committee of The University of Queensland, Australia.

## Statistical analysis

The proportion of invasive specimens for patients under 40, or 40 and over, were compared using Fisher's exact tests.<sup>9</sup> The average Breslow thickness of tumours definitively excised by GPs was compared with those excised by other specialists using an unpaired Mann–Whitney test (chosen due to results of appropriate normality testing).<sup>10,11</sup> In both cases, GraphPad Prism 9.3.0 software was used for analysis,  $P < 0.05$  was considered significant, and two-sided tests were used.

Survival and tumour-free survival probabilities were estimated using the Kaplan–Meier model. Survival analysis included only patients with primary invasive melanomas with known Breslow thickness ( $n = 205$ , 115 males, mean age: 60 years). One patient with an invasive melanoma of unknown Breslow thickness was excluded from analysis (desmoplastic subtype, sentinel lymph node biopsy (SLNB) negative, negative for metastasis and surviving). If multiple melanomas were recorded in the same patient, only the thickest melanoma was included in the survival analysis. All survival analyses were performed using the software package 'survival' and R.<sup>12</sup>

## RESULTS

We analysed 589 patients with 637 melanomas treated by 27 GPs in 2013. Most patients (58.9%) were males, and melanoma incidence peaked in the seventh decade (Fig. 1, Table 1).

Most (65%) of the 637 melanomas were *in situ*, and of 213 primary invasive melanomas with known Breslow thickness, in 205 unique patients, 72.3% were thin (Breslow thickness  $\leq 1$  mm).

Patients aged less than 40 years had fewer melanomas, but in that cohort most melanomas were invasive, a higher proportion compared with those aged 40 years or older ( $P < 0.0001$ ) (Fig. 1). Most patients (93.5%) had a single melanoma in 2013, 5.6% had two, and the balance ( $n = 5$ ) had between 3 and 7 melanomas. Only 8.7% of patients had a history of a first-degree relative with melanoma, but 22.8% had previous melanoma and the majority (52.6%) had previous keratinocyte carcinoma (Table 1).


Most (55.9%) melanomas were diagnosed following an elliptical excision biopsy, the balance by shave to mid-dermis (32.2%), punch (8.5%) and saucerisation (deep to subcutis) (1.3%) (Table 2). Biopsy margins were uninvolved in 88.8% of elliptical excision biopsy specimens compared with 44.9%, 27.8% and 37.5% for shave, punch and saucerisation biopsies respectively (Table 2). The rates of unintended positive margins were 4.5% for ellipses, 38.3%, for shaves and 40% for punch biopsies.

Shave biopsy was preferred, by a narrow margin, for lesions 10.1–20 mm in diameter, but elliptical excision biopsy was preferred for all melanomas smaller or larger with known diameter (Table 3). For lesions with known diameter, 65.6% of punch biopsies were performed on small lesions  $\leq 6$  mm in diameter.

Most superficial spreading melanomas (60.3%) were subjected to elliptical excision biopsy, but lentiginous melanoma was subjected to excision and shave biopsy with similar frequency (45.4% and 43.8% respectively) (Table 3).

The diagnostic procedure was intended as definitive treatment for 9.4% ( $n = 60$ ) of the 637 melanomas, but further surgery was required for 29 of these to achieve appropriate margins.

For patients with primary invasive melanomas ( $n = 205$ ), either thin ( $\leq 1$  mm) or thick, SLNB was discussed with 22 and 46, and proceeded with for 2 and 30 of them, respectively. Of the 32 SLNB performed, 5 were positive, all for thick melanomas, and all had completion lymphadenectomy. Of the five patients with positive SLNB, one had subsequent lymph node metastasis but was lost to follow-up, and four were surviving in 2020, without documented disease progression. Of 27 patients with negative SLNB, four were lost to follow-up, two died from non-melanoma causes, one had subsequent lymph node and distant metastasis followed by melanoma-specific death, and one had just distant metastasis followed by melanoma-specific death with 19 surviving disease-free.



**Figure 1** Numbers of *in situ* and invasive melanomas by age. Exact counts are shown on corresponding bar segments. A single primary invasive melanoma with unknown thickness was excluded from this analysis. Statistical analysis to compare proportion of invasive and *in situ* melanomas for those aged under 40, or 40 and over, were performed using a Fisher's exact test.

**Table 1** Patient characteristics

	n (%)
Number of Patients	589 (100)
Gender (male)	347 (58.9)
Patients with melanoma <i>in situ</i> *	388
Patients with primary invasive melanoma*	205
Patient with primary invasive melanoma thickness unknown	1
Patients with metastatic melanoma*	9
Age Brackets:	
0–9	0 (0)
10–19	1 (0.2)
20–29	16 (2.7)
30–39	36 (6.1)
40–49	68 (11.5)
50–59	96 (16.3)
60–69	176 (29.9)
70–79	126 (21.4)
80–89	59 (10.0)
90–99	11 (1.9)
100+	0 (0)
Number of Melanomas in 2015:	
1	551 (93.5)
2	33 (5.6)
3	3 (0.5)
4	1 (0.2)
5	0 (0)
6	0 (0)
7	1 (0.2)
Past History NMSC:	
Yes	310 (52.6)
No	272 (46.2)
Unknown	7 (1.2)
Past History of Melanoma:	
Yes	154 (22.8)
No	451 (76.6)
Unknown	4 (0.7)
Family History Melanoma:	
Yes	51 (8.7)
No	437 (74.2)
Unknown	101 (17.1)

\*Patients with multiple melanomas in 2015 may appear in more than one category. Note: the single primary invasive melanoma with unknown thickness was excluded from further analyses.

Definitive re-excision was performed by the treating GP for 74.9% of the melanomas, with 10.8% and 6.8% being treated by plastic and general surgeons respectively (Fig. 2, Table S1). GPs excised 84.3% of *in situ* melanomas. The average Breslow thickness of invasive melanomas definitively excised by GPs was 0.67 mm (range 0.07–8 mm), and of those referred to and excised by other specialists, 1.99 mm (range 0.15–10 mm) ( $P < 0.0001$ ). Plastic surgeons definitively excised similar numbers of *in situ* and invasive melanomas, 47.8% from females, most on the face, including the nose and ear, while those treated by general surgeons were mainly invasive, only 34.9% being from females, most not on the face, with none on nose or ear.

Current Australasian guidelines in 2015<sup>15</sup> (5 mm peripheral clinical margins for melanoma *in situ*, and 10 mm, or 10–20 mm, for Breslow thickness  $\leq 1$  mm or  $> 1$  mm

**Table 2** Melanoma Diagnostic Management

	n (%)	Intended complete Sample	Clear margin
		n	n
Melanomas	637 (100)	519	452
Biopsy method:			
Ellipse	356 (55.9)	351	316
Shave (to mid-dermis)	205 (32.2)	149	92
Punch	54 (8.5)	25	15
Saucerisation (includes subcutis)	8 (1.3)	4	5
Other	14 (2.2)	10	6

respectively, with deep margins through full subcutis for all melanomas) were adhered to for 95.1% of excisions for peripheral margins (Table S1). Recommended deep margins were complied with for 55.6% of excisions, 41.4% alternatively having the deep margin within subcutis. For 4.2% of melanomas ( $n = 26$ ), no definitive re-excision was performed, and as a result, there were seven melanomas with deep clearance recorded as being within dermis (Table S1).

Melanoma staging was upgraded following definitive re-excision for 10 invasive melanomas, five due to positive SLNB. Of the remaining 5, the preceding biopsy was ellipse ( $n = 2$ ), shave biopsy ( $n = 2$ ) and punch biopsy ( $n = 1$ ). Both radial and deep margins were positive for one ellipse and one shave, and the deep margin was positive for the other ellipse and shave, with no margin positivity reported for the punch.

Although in 2015, there was no Australasian qualification in dermatopathology, as distinct from anatomical pathology, 347 (54%) of the 637 melanomas in the current study were histopathologically assessed by pathologists who reportedly identified themselves as dermatopathologists.

Outcomes for the 205 unique patients with at least one primary invasive melanoma in 2015 are presented in Figure 3.

In four cases, a subsequent lesion arose continuously with a scar from a melanoma excised in 2015. Three were confirmed as melanoma, while the other, arising in 2015, was histopathologically diagnosed as (dysplastic) naevus. The three recurrent melanomas were all on the face, two of the preceding melanomas being lentiginous and the other superficial spreading.

Fourteen patients diagnosed with at least one primary invasive melanoma in 2015 had subsequent metastasis (Table S2). Most (64.3%,  $n = 9$ ) of these were male, with mean age 74.6 years (range 46–92). Two had multiple invasive melanomas in 2015, one with three (as well as four *in situ*) and the other with two. Three of these 14 melanomas were located on each of the back and leg, two on each of the face, neck and thigh, one on the scalp and one on the arm. Seven were nodular, five superficial spreading and two lentiginous. Mean Breslow thickness was 3.9 mm (range 0.5–10.0). For seven of the nine patients with melanoma-specific death, that death was linked to a single

**Table 3** Diagnostic surgical procedures by melanoma subtype, diameter and margin involvement (positivity)

	Biopsy Type					
	Total	Ellipse	Shave (to mid-dermis)	Punch	Saucerisation (includes subcutis)	Other
Total number of specimens N (%)	637 (100)	356 (100)	205 (100)	54 (100)	8 (100)	14 (100)
Subtype:						
Superficial Spreading Melanoma (SSM)	320 (50.2)	193 (54.2)	92 (44.9)	29 (53.7)	4 (50.0)	2 (14.3)
Lentiginous (including mucosal/acral)	249 (39.1)	113 (31.7)	109 (53.2)	16 (29.6)	5 (37.5)	8 (57.1)
Nodular	27 (4.2)	20 (5.6)	2 (1.0)	4 (7.4)	1 (12.5)	0 (0)
Spitzoid	5 (0.8)	5 (1.4)	0 (0)	0 (0)	0 (0)	0 (0)
Mixed lentiginous SSM	5 (0.8)	3 (0.8)	2 (1.0)	0 (0)	0 (0)	0 (0)
Desmoplastic	4 (0.6)	2 (0.6)	0 (0)	2 (3.7)	0 (0)	0 (0)
Naevoid	1 (0.2)	1 (0.5)	0 (0)	0 (0)	0 (0)	0 (0)
Not specified	17 (2.7)	13 (3.7)	0 (0)	2 (3.7)	0 (0)	2 (14.3)
Metastasis	9 (1.4)	6 (1.7)	0 (0)	1 (1.9)	0 (0)	2 (14.3)
Diameter (mm):						
≤5	31 (4.9)	17 (4.8)	5 (2.4)	9 (16.7)	0(0)	0 (0)
5.1–6	145 (22.8)	85 (23.9)	46 (22.4)	12 (22.2)	0(0)	2 (14.3)
6.1–10	200 (31.4)	130 (36.5)	61 (29.8)	4 (7.4)	2 (25.0)	3 (21.4)
10.1–20	175 (27.5)	100 (28.1)	61 (29.8)	6 (11.1)	2 (25.0)	6 (42.9)
>20	19 (3.0)	13 (3.7)	4 (2.0)	2 (3.7)	0(0)	0 (0)
Unknown	67 (10.5)	11 (3.1)	28 (13.7)	21 (38.9)	4 (50.0)	3 (21.4)
Biopsy positive margins:						
No	432 (67.8)	316 (88.8)	92 (44.9)	15 (27.8)	3 (37.5)	6 (42.9)
Yes, radial margin	160 (25.1)	36 (10.1)	91 (44.4)	26 (48.1)	2 (25.0)	5 (35.7)
Margins not reported	7 (1.1)	0 (0)	5 (2.4)	1 (1.9)	0 (0)	1 (7.1)
Yes, deep margin	6 (0.9)	1 (0.5)	3 (1.5)	0 (0)	2 (25.0)	0 (0)
Yes, both radial and deep margin	28 (4.4)	3 (0.8)	13 (6.3)	11 (20.4)	1 (12.5)	0 (0)
Unknown	4 (0.6)	0 (0)	1 (0.5)	1 (1.9)	0(0)	2 (14.3)

A single primary invasive melanoma with unknown thickness was excluded from this analysis.

primary invasive melanoma. Five of these were nodular and two superficial spreading, one with a Breslow thickness of only 0.5 mm.

The median follow-up time of the 205 patients with primary invasive melanomas (115 males, mean age: 60 years) was 7.0 years (interquartile range: 6.5–7.3). The 5-year survival rate for all patients with invasive melanoma was 95.2% (95% CI: 91.2–98.5%).


## DISCUSSION

Studies on melanoma demographics, diagnosis and management by GPs are limited, and the available evidence from Australasia suggests that while gender and age distribution of patients are similar to tertiary care-based studies, the proportion of *in situ* and thin-invasive melanomas is higher.<sup>7,14</sup> Comparing the current study of 589 patients, with a Brisbane, Queensland, primary care-based study of 380 patients,<sup>14</sup> the proportion of males was similar at 58.9% *vs* 57.1% as was the mean age at diagnosis, of 60 years (range 18–96) *vs* 57 years (range 19–95). In both of these primary care studies, most melanomas were *in situ* (65% *vs* 74.2% in the current and Brisbane study respectively) contrasting with only 23.8% being *in situ* in a tertiary care-based study on 5141 melanomas in Victoria<sup>15</sup> and only 39.9% in a New Zealand, population-based study of 974 patients.<sup>16</sup> Considering primary invasive melanomas, 71.3% in the current study were thin (≤1 mm thick)


compared with 84% in the Brisbane primary care study<sup>14</sup> (<0.8 mm thick) contrasting with only 47.4% in the tertiary care-based study in Victoria (≤1 mm thick).<sup>15</sup>

Australasian guidelines applicable in 2013<sup>15</sup> and in Australia currently<sup>17</sup> recommend elliptical excision biopsy for suspected melanoma, with 2-mm peripheral margins undermined in the subcutis, and in the current study, this was adhered to for 55.9% of lesions. Shave biopsy has been proposed as an expedient and reasonable alternative<sup>18</sup> in certain circumstances, and this was the method used for 32.2% of cases in the current study. The fact that unintended positive margin involvement was eightfold more likely for shave *versus* excisional biopsy (Table 2) is a reminder of potential hazards to consider when deviating from guidelines.

For excisional-biopsy specimens, the objective was complete sampling for 95%, compared with 75% for shave biopsy (Table 2). This was not related to large size as ellipses were favoured for all lesions with documented diameters and were strongly favoured for lesions >20 mm diameter (Table 3). Punch biopsy is known to be the method most associated with errors in diagnosis of melanoma.<sup>19</sup> Excluding cases with unknown diameter, 63.6% of punch biopsies were performed on lesions ≤6 mm. While for all punch biopsies, there were high rates of both radial and deep margin positivity, there were no cases of documented deep margin positivity where the radial margins were reported clear (Table 3). A similar pattern has



**Figure 2** Practitioners providing the definitive treatment (secondary wide excision) of *in situ* and invasive melanomas. Exact counts are shown above the corresponding bar. A single primary invasive melanoma with unknown thickness was excluded from this analysis. Abbreviations: GP, general practitioner; WLE, wide local excision.



**Figure 3** Details of outcomes for 205 patients with at least one primary invasive melanoma in 2015. Details of each segment are presented in adjacent text. One patient with a primary invasive melanoma of unknown Breslow thickness was excluded from analysis (sentinel lymph node biopsy negative, negative for metastases and surviving). Abbreviations: SLNB, sentinel lymph node biopsy; LNMet, lymph node metastasis; DMet, distant metastasis; IntransitMet, in-transit cutaneous metastasis.

been previously documented<sup>20</sup> suggesting that punch biopsy is being favoured where the punch comfortably encompasses the lesion, although it must be accepted that even in this situation undetected positive margins will be frequent.<sup>21</sup> The fact that one punch biopsy with reported clear margins was followed by upstaging of the diagnosis following wide excision, is a reminder of the limitations of margin-assessment for punch biopsy specimens.

Superficial spreading melanomas typically have well-defined margins,<sup>22</sup> and 60% in the current study were diagnosed following elliptical excision biopsy in contrast to lentiginous melanomas, frequently with indistinct margins,<sup>22</sup> which were just as likely to be diagnosed following a shave or elliptical excision biopsy (Table 3).

In the current study, 74.9% of lesions were definitively managed by the treating GP, 17.6% by a surgeon and 0.3% by a dermatologist (Table S1), compared with 49%, 34% and 16% reported nationally in Australia in 2013–2014 respectively.<sup>5</sup> Referral for definitive treatment of a melanoma by a GP is likely to be in response to a surgical challenge, probably explaining the low rate of referral to dermatologists in this context. The distribution of definitive management between plastic and general surgeons with respect to patient gender, anatomical site and invasive status was consistent with the traditional focus of each of these specialties.

For the vast majority (95.1%) of definitive re-excisions, the peripheral margin clearance complied with guidelines (Table S1). The lower compliance with guidelines for deep margins, of 55.6%, with 41.4% alternatively being excised at the level of the subcutis, is arguably reasonable, given the context of current Australian guidelines,<sup>17</sup> which include an option of measuring the deep margin as for the peripheral margin where the subcutis is thick. Adverse outcomes were not increased with deep margins in the subcutis. Of index primary invasive melanomas with the deep margin within the subcutis, 4.5% had adverse outcomes ( $n = 2/46$ ) compared with 7.5% with deeper margins ( $n = 12/159$ ).

Guidelines recommend a discussion with the patient concerning SLNB with thick melanomas (>1 mm) and some high-risk thin melanomas<sup>15</sup> although this is not without controversy.<sup>25</sup> In the current study, SLNB was discussed with 80.7% of patients with thick melanomas, and performed in 52.6%, compared with rates ranging from 33% to 53% in tertiary care-based studies.<sup>24</sup> The SLNB positivity rate in the current study of 15.6% compared with 20.8% in the Multi-centre Selective Lymphadenectomy Trial.<sup>25</sup> Of patients with positive SLNB, 80% remained disease-free compared with a published rate of 24%<sup>25</sup> and of those with negative SLNB with follow-up data, 8.7% progressed to metastasis compared with a published rate of 11%.<sup>25</sup>

The most useful indicator of adequacy of wide local excision is the rate of local recurrence.<sup>26</sup> In the current study, there were three documented local recurrences of melanoma, four if the 'recurrence' diagnosed as (dysplastic) naevus is included. This would give a local recurrence rate of 0.6%, compared with 1.56% of cases in a study of 11 290 thin (T1) melanomas.<sup>27</sup>

The characteristics of the 14 melanomas progressing to metastatic disease, including the nine that progressed to melanoma-specific death, are consistent with tertiary care-based studies (Table S2). Half of these 14 melanomas were located on previously defined high-risk sites on the scalp, neck, back and arm.<sup>28</sup> Nodular melanoma is disproportionately associated with adverse outcomes,<sup>29</sup> and although it only comprised 12.6% of the invasive melanomas in the current study, it was responsible for 50% of the 14 cases progressing to metastatic disease. The average Breslow thickness of the 14 melanomas progressing to metastasis, 3.9 mm, is consistent with the known association of this measurement with adverse outcomes.<sup>25</sup> However, the fact that two of the melanomas were thin, one with a Breslow thickness of 0.5 mm resulting in melanoma-specific death, is a reminder that until technology can prospectively identify instances of melanoma overdiagnosis (diagnosis of melanomas that will not progress to adverse outcomes), all melanomas must be managed as potentially life-threatening.

With respect to patients with multiple primary invasive melanomas, a study from Queensland, Australia, on 32,861 patients with melanomas, found that the hazard ratio of death within 10 years was two times higher for those with two melanomas, and nearly three times higher for those with three, compared with a person with a single melanoma.<sup>30</sup> In the current study, 35% of patients with multiple primary invasive melanomas in 2015 progressed to metastatic disease (2 out of 6 patients), compared with only 6% of those with a single primary invasive melanoma (12 out of 199 patients). A larger sample size is necessary to test the significance of this trend.

Notwithstanding the limitations of comparing survival metrics in the current study with age-adjusted population-based metrics, melanoma-specific 5-year survival in the current study of 95.2%, is similar to national figures for Australia (92%) and New Zealand (90%).

## LIMITATIONS

Completeness and accuracy of data were not independently verified, and the absolute number of melanoma patients was small, as a proportion of the total managed by GPs in Australasia in 2015. This study is based on a subset of a database, and the participants are not necessarily typical of Australasian GPs. With respect to their level of qualification, the majority have a Master's degree or PhD in the field of skin cancer, and as an indication of their experience, they each excised an average of 23.6 melanomas in 2015, compared with national figures for GPs, surgeons and dermatologists of 0.7, 7.5 and 13.8, respectively.<sup>5</sup>

## CONCLUSIONS

In this study on melanoma management and outcomes for a subset of GPs in Australasia, patient gender and age demographics were similar to those of tertiary care-based studies, but the majority of melanomas were *in situ* or thin-invasive. While melanoma *in situ* predominated overall, invasive melanoma was more prevalent under the

age of 40 years. Diagnostic and therapeutic management was closely aligned with current guidelines, with elliptical excision biopsy followed by wide excision being performed for the majority. The much higher rate of margin involvement with shave and punch biopsies, along with the fact that most punches were performed on small lesions which could easily have been excised, argue strongly in favour of a recommendation for elliptical excision biopsy. Most *in situ* and thin melanomas were definitively re-excised by GPs, with thick melanomas preferentially referred to surgeons. Melanomas with adverse outcomes, as in tertiary care-based studies, tended to be thick, half of nodular subtype, but with all major subtypes, as well as thin melanomas, being represented. Five-year survival with respect to invasive melanoma was at least as favourable as national population-based metrics. Further studies are warranted.

### ETHICAL APPROVAL

The Human Ethics Research Office of The University of Queensland, Australia, provided ethics exemption for this study.

### AUTHOR CONTRIBUTIONS

Author Wilson administers SCARD and provided the raw data for analysis. Author C Rosendahl performed data cleaning. Authors Hay, Keir, Jimenez Balcells, Coetzer-Botha, Wilson, Clark, Kittler and C Rosendahl made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, were involved in drafting and critically revising and finally approving the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work have been appropriately investigated and resolved. Harald Kittler calculated the survival metrics. Author N Rosendahl prepared the Tables and Figures and performed the statistical analyses and takes responsibility for data analysis, made substantial contributions to conception and design, was involved in drafting and critically revising and finally approving the manuscript and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work have been appropriately investigated and resolved. The other authors were all involved in data acquisition, were involved in critically revising and finally approving the manuscript and agree to be accountable for relevant aspects of the work in ensuring that questions related to the accuracy or integrity of the work have been appropriately investigated and resolved. All the authors have participated sufficiently to take public responsibility for appropriate portions of the content.

### REFERENCES

1. *Melanoma of the skin statistics*. 2021 [cited 2021 20 August 2021]. Available from: <https://www.canceraustralia.gov.au/cancer-types/melanoma/statistics>

2. *New cancer registrations* 2018. Ministry of Health NZ; 2018 [cited 2021 20 August]. Available from: <https://www.health.govt.nz/publication/new-cancer-registrations-2018>
3. Wu A, Rosen R, Selva D *et al*. Proportion of melanoma excisions performed by different specialties in Australia. *Australas. J. Dermatol.* 2018; **59**: 243–5.
4. Curchin DJ, Harris VR, McCormack CJ *et al*. Changing trends in the incidence of invasive melanoma in Victoria, 1985–2015. *Med. J. Aust.* 2018; **208**: 265–9.
5. *Melanoma of the skin statistics*. Australian government; 2021 [cited 2021 November 20]. Available from: <https://www.canceraustralia.gov.au/cancer-types/melanoma/statistics>
6. New Zealand cancer survival overview. *New Zealand government Ministry of Health*; [cited 2021 November 20]. Available from: <https://www.health.govt.nz/system/files/documents/publications/cancer-patient-survival-1994-2011-apr15-v2.pdf>
7. Jimenez Balcells C, Hay J, Keir J *et al*. Characteristics of 637 melanomas documented by 27 general practitioners on the Skin Cancer Audit Research Database. *Australas. J. Dermatol.* 2021; **62**: 496–503.
8. Rosendahl C, Hansen C, Cameron A *et al*. Measuring performance in skin cancer practice: the SCARD initiative. *Int. J. Dermatol.* 2011; **50**: 44–51.
9. Fisher RA. Statistical Methods for Research Workers. In: Kotz S, Johnson NL (eds). *Breakthroughs in Statistics: Methodology and Distribution*. New York, NY: Springer New York, 1992; 66–70.
10. Mann HB, Whitney DR. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other. *Ann. Math. Stat.* 1947; **18**: 50–60, 11.
11. Wilcoxon F. Individual Comparisons by Ranking Methods. *Biometrics* 1945; **1**: 80–5.
12. *R: A language and environment for statistical computing*. R Core Team (2015); 2015 [cited 2021 November 20]. Available from: <http://www.R-project.org/>
13. *Clinical Practice Guidelines for Australia and New Zealand for the Management of Melanoma*. Australian Cancer Network and Ministry of Health NZ. 2008 [cited 2021 November 21]. Available from: <https://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf>
14. Green AC, Pandeya N, Morton S *et al*. Early detection of melanoma in specialised primary care practice in Australia. *Cancer Epidemiol.* 2021; **70**: 101872.
15. Wee E, Wolfe R, McLean C *et al*. The anatomic distribution of cutaneous melanoma: A detailed study of 5141 lesions. *Australas. J. Dermatol.* 2020; **61**: 125–35.
16. Elwood JM, Kim SJH, Ip KHK *et al*. In situ and invasive melanoma in a high-risk, New Zealand, population: A population-based study. *Australas. J. Dermatol.* 2019; **60**: 38–44.
17. *Clinical Practice Guidelines for the Diagnosis and Management of Melanoma*. 2021 [cited 2021 December 3]. Available from: <https://wiki.cancer.org.au/australia/Guidelines:Melanoma>
18. Zager JSMDF, Hochwald SNMDF, Marzban SSBS *et al*. Shave Biopsy Is a Safe and Accurate Method for the Initial Evaluation of Melanoma. *J. Am. Coll. Surg.* 2011; **212**: 454–60.
19. Ng JC, Swain S, Dowling JP *et al*. The Impact of Partial Biopsy on Histopathologic Diagnosis of Cutaneous Melanoma: Experience of an Australian Tertiary Referral Service. *Arch. Dermatol.* 2010; **146**: 234–9.
20. Hieken TJ, Hernández-Irizarry R, Boll JM *et al*. Accuracy of Diagnostic Biopsy for Cutaneous Melanoma: Implications for Surgical Oncologists. *Int. J. Surg. Oncol.* 2013; **2015**: 196495–7.
21. Chang TTMD, Somach SCMD, Wagamon KMD *et al*. The inadequacy of punch-excised melanocytic lesions: Sampling through the block for the determination of “margins”. *J. Am. Acad. Dermatol.* 2008; **60**: 990–5.
22. *Report Summarizes Melanoma Study Findings from University of Sydney (Melanoma In Situ: a Critical Review and Re-*

- evaluation of Current Excision Margin Recommendations*). Health Medicine Week 2021.
25. Coldiron BMMD, Dinehart SMD, Rogers HWMD. Sentinel lymph node biopsy and completion lymph node dissection for malignant melanoma are not standard of care. *Clin. Dermatol.* 2009; **27**: 350–4.
  24. Rapport F, Smith AL, Cust AE *et al.* Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. *BMJ Open* 2020; **10** (2): e032636-e.
  25. Morton DL, Thompson JF, Cochran AJ *et al.* Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. *N. Engl. J. Med.* 2014; **370**: 599–609.
  26. Weyers W. "Personalized Excision" of Malignant Melanoma-Need for a Paradigm Shift in the Beginning Era of Personalized Medicine. *Am. J. Dermatopathol.* 2019; **41**: 884–96.
  27. MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, *et al.* The association between excision margins and local recurrence in 11,290 thin (T1) primary cutaneous melanomas: a case-control study. *Ann. Surg. Oncol.* 2015; **23**: 1082–9.
  28. Garbe C, Büttner P, Bertz J *et al.* Primary cutaneous melanoma. Prognostic classification of anatomic location. *Cancer* 1995; **75**: 2492–8.
  29. Smithson SL, Pan Y, Mar V. Differing trends in thickness and survival between nodular and non-nodular primary cutaneous melanoma in Victoria, Australia. *Med. J. Aust.* 2015; **205**: 20.
  30. Youlden DR, Baade PD, Soyer HP *et al.* Ten-Year Survival after Multiple Invasive Melanomas Is Worse than after a Single

Melanoma: a Population-Based Study. *J. Invest. Dermatol.* 2016; **136**: 2270–6.

## Supporting Information

Additional Supporting Information may be found online in Supporting Information:

**Table S1** Definitive management providers, clinical guidelines adherence, deep margin location, sentinel lymph node biopsy metrics and impact of definitive excision on tumour staging. A single primary invasive melanoma with unknown thickness was excluded from this analysis. Abbreviation: GP, general practitioner; SLNB, sentinel lymph node biopsy.

**Table S2** Characteristics of patients and their index melanomas (thickest melanoma as per Breslow thickness) for those with at least one primary invasive melanoma in 2013 who progressed to in-transit cutaneous, nodal or distant metastasis (n = 14) (single primary invasive melanoma with unknown thickness excluded). Abbreviations: NM, nodular melanoma; SSM, superficial spreading melanoma; LM, lentiginous melanoma; SLNB, sentinel lymph node biopsy.